WO2008030367A3 - Selective myostatin inhibitors - Google Patents
Selective myostatin inhibitors Download PDFInfo
- Publication number
- WO2008030367A3 WO2008030367A3 PCT/US2007/018974 US2007018974W WO2008030367A3 WO 2008030367 A3 WO2008030367 A3 WO 2008030367A3 US 2007018974 W US2007018974 W US 2007018974W WO 2008030367 A3 WO2008030367 A3 WO 2008030367A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myostatin inhibitors
- selective
- selective myostatin
- inhibitors
- follistatins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provided are mutant follistatins that act as selective myostatin inhibitors, as well as methods of using the same to treat muscle wasting disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84184106P | 2006-09-01 | 2006-09-01 | |
| US60/841,841 | 2006-09-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008030367A2 WO2008030367A2 (en) | 2008-03-13 |
| WO2008030367A3 true WO2008030367A3 (en) | 2008-10-16 |
Family
ID=39157757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/018974 Ceased WO2008030367A2 (en) | 2006-09-01 | 2007-08-29 | Selective myostatin inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008030367A2 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TW201627320A (en) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | Variants derived from ActRIIB and their uses |
| EP3363453A1 (en) | 2008-06-26 | 2018-08-22 | Acceleron Pharma Inc. | Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders |
| KR102024444B1 (en) | 2008-06-26 | 2019-09-23 | 악셀레론 파마 인코포레이티드 | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR102133683B1 (en) | 2009-09-09 | 2020-07-14 | 악셀레론 파마 인코포레이티드 | Actriib antagonists and dosing and uses thereof |
| US20150276766A1 (en) | 2012-10-24 | 2015-10-01 | Celgene Corporation | Biomarker for use in treating anemia |
| ES2652437T3 (en) | 2012-11-02 | 2018-02-02 | Celgene Corporation | Activin-actrii antagonists and uses for the treatment of bone disorders and other disorders |
| US9957309B2 (en) | 2013-01-25 | 2018-05-01 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| BR112016024319B1 (en) | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USE OF A COMPOSITION COMPRISING AN ActRII ANTAGONIST FOR THE MANUFACTURING OF A MEDICATION FOR TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL ANEMIA |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| JP6568110B2 (en) | 2014-06-04 | 2019-08-28 | アクセルロン ファーマ， インコーポレイテッド | Methods and compositions for treatment of disorders with follistatin polypeptides |
| CN107135646B (en) | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | Methods and compositions for treating ulcers |
| MA41052A (en) | 2014-10-09 | 2017-08-15 | Celgene Corp | TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS |
| CN107533040B (en) | 2014-12-03 | 2022-03-29 | 细胞基因公司 | activin-ACTRII antagonists and uses for treating anemia |
| MA41119A (en) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA |
| AU2016238254B2 (en) | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| MA41919A (en) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
| MA41916A (en) | 2015-04-06 | 2021-04-14 | Acceleron Pharma Inc | TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEIVER HETEROMULTIMERS AND THEIR USES |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| JP7072507B2 (en) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | Methods for treating eye disorders |
| SG11201807400TA (en) * | 2016-03-04 | 2018-09-27 | Shire Human Genetic Therapies | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| DK3368069T3 (en) * | 2016-06-13 | 2020-11-02 | Scholar Rock Inc | USE OF MYOSTATINI INHIBITORS AND COMBINATION THERAPIES |
| SI3496739T1 (en) | 2016-07-15 | 2021-06-30 | Acceleron Pharma Inc. | Compositions comprising actriia polypeptides for use in treating pulmonary hypertension |
| SI3490582T1 (en) | 2016-07-27 | 2024-09-30 | Acceleron Pharma Inc. | Compositions for use in treating myelofibrosis |
| AU2017340504A1 (en) | 2016-10-05 | 2019-04-11 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | A therapeutic method of increasing muscle mass in a subject |
| US20220380422A1 (en) * | 2021-05-28 | 2022-12-01 | Lirsamax, Inc. | Method for treating muscle atrophy and/or obesity and composition for use in said method |
| TW202430247A (en) | 2022-12-22 | 2024-08-01 | 美商供石公司 | Selective and potent inhibitors of myostatin activation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005100563A1 (en) * | 2004-04-15 | 2005-10-27 | Techno Network Shikoku Co., Ltd. | Follistatin mutant polypeptide |
| US20070135336A1 (en) * | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
-
2007
- 2007-08-29 WO PCT/US2007/018974 patent/WO2008030367A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070135336A1 (en) * | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| WO2005100563A1 (en) * | 2004-04-15 | 2005-10-27 | Techno Network Shikoku Co., Ltd. | Follistatin mutant polypeptide |
Non-Patent Citations (2)
| Title |
|---|
| SIDIS ET AL.: "Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins.", ENDOCRINOLOGY, vol. 147, 2006, pages 3586 - 3597 * |
| TSUCHIDA K.: "Activins, Myostatin and Related TGF-R Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune Disorders.", CURRENT DRUG TARGETS - IMMUNE, ENDOCRINE & METABOLIC DISORDERS, vol. 4, 2004, pages 157 - 166 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008030367A2 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008030367A3 (en) | Selective myostatin inhibitors | |
| WO2009036175A3 (en) | F1f0-atpase inhibitors and related methods | |
| WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
| WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
| WO2008128072A3 (en) | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders | |
| EP2023926A4 (en) | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders | |
| IL193080A0 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
| PL1993985T3 (en) | Process for the preparation of 1,2-propanediol | |
| WO2010077740A3 (en) | Novel antiviral compounds, compositions, and methods of use | |
| WO2008095086A3 (en) | Topiramate plus naltrexone for the treatment of addictive disorders | |
| WO2009042114A3 (en) | Phenazine derivatives and uses thereof | |
| UA99936C2 (en) | Biaryl substituted azabicyclic alkane derivatives | |
| WO2006015159A3 (en) | Potassium channel inhibitors | |
| WO2007133622A3 (en) | Selective inhibitors of rock protein kinase and uses thereof | |
| WO2009085270A3 (en) | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions | |
| WO2010071783A8 (en) | Thiazoles as cannabinoid receptor ligands | |
| WO2009158719A3 (en) | Methods and compositions for treating disorders | |
| PT2229369T (en) | 6,7-dialkoxy-quinazoline derivatives useful for treatment of cancer-related disorders | |
| IL190730A0 (en) | Potassium channel inhibitors | |
| WO2008027600A3 (en) | Imatinib compositions | |
| WO2010030891A3 (en) | Aryl guanidine f1f0-atpase inhibitors and related methods | |
| WO2007136741A3 (en) | N-desmethyl-doxepin and methods of using the same to treat sleep disorders | |
| GB2465814B (en) | Method,composition and device for the treatment of enzymes and saccharides disorders | |
| WO2007050348A3 (en) | Potassium channel inhibitors | |
| WO2008057681A3 (en) | Thiophene compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07837462 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07837462 Country of ref document: EP Kind code of ref document: A2 |